pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Type 2 Diabetes · news · pharmadog
← back to Type 2 Diabetes
News mentioning Type 2 Diabetes
105
stories
Sep 29, 26
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 25, 26
STAT+: Lilly wins approval for once-weekly insulin shot
stat
Sep 25, 26
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
Sep 25, 26
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
Sep 24, 26
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
Sep 24, 26
FDA approves Eli Lilly's once-weekly insulin pen, setting up rivalry with Novo
endpoints
Sep 24, 26
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
Sep 24, 26
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
Sep 23, 26
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
Sep 22, 26
Vertex opens up larger kidney disease opportunity with mid-stage readout
biospace
Sep 22, 26
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
Sep 22, 26
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
Sep 22, 26
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
Sep 22, 26
Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes
endpoints
Sep 22, 26
Vertex’s midstage data amplify kidney disease market opportunity
fiercebiotech
Sep 22, 26
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 16, 26
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
Sep 11, 26
Medicaid will let states use ‘tiers’ to determine medical frailty
stat
Sep 9, 26
Kura spins diabetes work into a Lilly-backed biotech startup
biopharma dive
Sep 9, 26
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
Sep 9, 26
Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy
fiercebiotech
Sep 4, 26
Menarini signs $771M deal to take Gan & Lee GLP-1 to European market
fiercebiotech
Sep 3, 26
‘Tactical athletes’ get new guidance for cardiovascular fitness
stat
Sep 1, 26
As MAHA champions nutrition, it’s ignoring the experts, dietitians say
stat
Aug 31, 26
The next frontier: Advancing foundation models with multimodal data
biopharma dive
Aug 28, 26
Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro
biospace
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
← prev
page 2 of 4
next →